Candriam S.C.A. I Mab Transaction History
Candriam S.C.A.
- $18.4 Billion
- Q3 2025
A detailed history of Candriam S.C.A. transactions in I Mab stock. As of the latest transaction made, Candriam S.C.A. holds 1,132,563 shares of IMAB stock, worth $4.72 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,132,563
Previous 1,132,563
-0.0%
Holding current value
$4.72 Million
Previous $2.74 Million
56.24%
% of portfolio
0.02%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding IMAB
# of Institutions
52Shares Held
34.5MCall Options Held
25KPut Options Held
42.3K-
Janus Henderson Group PLC London, X07.99MShares$33.3 Million0.01% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.98MShares$24.9 Million0.68% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$17.4 Million3.04% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.34MShares$13.9 Million0.02% of portfolio
-
Morgan Stanley New York, NY2.23MShares$9.31 Million0.0% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $347M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...